QUECTEL
16.5.2023 18:26:27 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces breaking ground for its new innovation Headquarter in Shanghai and also recently celebrated a significant milestone with the opening of its new Global Intelligent Manufacturing Center (GIMC) in Changzhou.
Delivering advanced IoT automation, the new GIMC facility features a fully functioning manufacturing production line that combines latest technologies, including edge intelligence, machine learning, robotics and machine vision solutions built with Quectel’s latest smart module technologies which significantly expands manufacturing capabilities to guarantee supply and reassure product quality for global customers. Designed and architected by a group of its own IoT experts, this state-of-the art IoT manufacturing center is equipped with the most advanced industrial automation technologies including:
- Fully automated warehouse storage system with 65,000 material cubicles, which can support 40 SMT lines material supply and operate 7x24 based on real-time workorders.
- End-to-end touchless process with Automatic Guided Vehicles to transport raw material to production lines, hand-over semi-products from SMT for testing and final packing with minimal manpower.
- 30 Fuji NXT-III SMT lines with Siemens MES monitoring system supporting production of up to 150 million modules per year.
- 85 Quectel Self Design Automatic Testing Stations with full testing log files onto each module produced.
- 40 Quectel Self Design Auto Inspection and Packing Systems.
The GIMC project started construction in September 2021 and will commence operation in 2023. The smart factory will further enhance Quectel’s production capabilities, strengthening its core competitiveness. The center occupies an area of 72,000 square meters, with a total construction space of 160,000 square meters. It is capable of manufacturing Quectel’s full range of modules, including 4G modules, 5G modules, smart modules, automotive grade modules, narrowband IoT modules, GNSS modules, Wi-Fi modules and antennas.
“Our new smart factory represents an important step toward the next generation of smart manufacturing and will guarantee both our product quality and production capacity, sufficient to meet various demanding requirements of our global customers,” said Patrick Qian, CEO of Quectel. “Applying IoT innovation to our own processes -- will not only help us enhance our industry leading quality -- it will also accelerate the expansion of the global IoT market and be a catalyst for the entire IoT eco-system.”
Quectel also recently broke ground for its new headquarters in Shanghai. “The new headquarter is designed to provide a modern, smart environment that makes it attractive for the best people to work, excel and innovate and that exceeds the highest standards in sustainability, health and wellness,” Mr. Qian continued.” It will host Quectel’s R&D center and IoT innovation showroom and will bring together some of the world’s greatest engineers and IoT leaders to accelerate innovation and drive the future of IoT”. The new headquarter of approximately 100,000 square meters will serve as a central hub for administrative and research and development functions but will also offer a wide range of amenities including sports facilities, conference spaces, outdoor gardens, catering services, and ample parking facilities. The company plans to officially inaugurate and begin operations at the new headquarters in 2025.
Founded in 2010, Quectel has consistently maintained rapid development and has become a leading global IoT provider of solutions covering cellular modules, Wi-Fi modules, smart modules, automotive modules, GNSS modules, antennas as well as connectivity and certification services.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom